Male physician holding the Revi device between his fingers while talking to patient out of view.
Male physician holding the Revi device between his fingers while talking to patient out of view.

Publications and guidelines

Male physician holding the Revi device between his fingers while talking to patient out of view.
Male physician holding the Revi device between his fingers while talking to patient out of view.

Changes to the AUA/SUFU Guideline for Idiopathic Overactive Bladder puts patients and their physician in control

Historically, “step therapy” has been utilized to treat urgency urinary incontinence (UUI), with behavioral therapy and medication being the first and second step in the treatment algorithm. However, “long-term compliance with these measures is poor, resulting in high rates of failure and patient frustration.” The new guideline now emphasizes “the importance of shared decision-making to select the best therapy or therapies, regardless of invasiveness, based on the patient’s needs, desires, and side effect tolerance.” Revi, a minimally invasive, patient-centric, implantable tibial neuromodulation system, is now included in the clinical care guidelines.

Publications

Learn how BlueWind Medical is continuing research to advance treatment for urge urinary incontinence (UUI) and overactive bladder (OAB)—such as with the BlueWind Revi™ System (formerly known as the RENOVA™ iStim and the BlueWind Medical Device)—through leading publications and journals. More publications are forthcoming; check back frequently for updates.

Two women sitting on a couch with the Revi wearable.

Revi demonstrated
proven efficacy and
safety in OASIS pivotal
study

Patients treated with Revi in the OASIS (OverActive Bladder Stimulation System Study) pivotal study reported high levels of satisfaction and experienced significant improvements in UUI symptoms as well as in quality of life, among other transformative benefits.